Skip to main content
Equibles
OM logo

OM · Outset Medical, Inc. · Metrics

Track OM — free

Use OM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.41 +0.18 (+4.26%) Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$79.83M
Shares
18.87M
Volume · Nov 9 47.03K Avg daily vol (3M) 149.78K

OM metrics

89 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.23
Market cap
$79.83M

Price action

23 metrics
Price change (1W)
+5.0%
Price change (30D)
+4.4%
Price change (3M)
-13.7%
Price change (6M)
+14.5%
Price change (YTD)
+14.0%
Price change (1Y)
-64.2%
Trailing year
Price change (5Y)
—
52-week high
$12.07
52-week low
$2.96
Change from 52-week high
-65.0%
Change from 52-week low
+42.9%
Annualized volatility
102.0%
Annualized volatility (3M)
78.1%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.9
RSI (14D)
54.9
Price vs SMA 50
+13.5%
Price vs SMA 200
+2.5%
Avg volume (3M)
149,782
Relative volume
0.3
Average dollar volume
$581,542

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
18.87M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.1×
reciprocal yield 1,712.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.7×
reciprocal yield 152.8%
P / book
1.0
reciprocal yield 104.4%
FCF yield
-53.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-89.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.7×
reciprocal yield 138.7%
EV / revenue historical average (5Y)
4.5×
reciprocal yield 22.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
42.0%
Operating margin
-51.2%
Trailing 12 months
Net margin
-58.3%
Gross profit (TTM)
$51.28M
Operating profit (TTM)
−$62.49M
Net income (TTM)
−$71.14M
Trailing 12 months
Diluted EPS (TTM)
$-2.45
FCF margin
-35.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$6,592.29
Gross profit per diluted share (TTM)
$2,772.28
Operating profit per diluted share (TTM)
$-3,386.70
EBITDA per diluted share (TTM)
$-3,225.80
Net income per diluted share (TTM)
$-3,853.79
Operating cash flow per diluted share (TTM)
$-2,292.87
Free cash flow per diluted share (TTM)
$-2,320.46
Capital expenditures per diluted share (TTM)
$27.59
R&D per diluted share (TTM)
$1,190.52
Stock compensation per diluted share (TTM)
$646.48
Book value per share
$6.99

Growth

11 metrics
Revenue growth YoY
+14.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$121.97M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.9%
Year over year · more shares
Revenue CAGR (3Y)
+1.2%
Revenue CAGR (5Y)
+19.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-85.4%
Return on assets
-30.9%
Debt / equity
0.8
Current ratio
4.9
EBITDA (TTM)
−$59.52M
Free cash flow (TTM)
−$42.89M
Quick ratio
3.9
Interest coverage
-4.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$72.71M
Latest balance sheet
Cash & equivalents
$33.94M
Total assets
$230.41M
Total debt
$96.24M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$42.38M
Capital expenditures (TTM)
$508,000
R&D (TTM)
$22.02M
SG&A (TTM)
—
Stock compensation (TTM)
$11.90M
R&D / revenue
18.1%
Stock compensation / revenue
9.8%

Ownership (13F)

9 metrics
13F filers
92
13F filer change QoQ
-8
Institutional ownership
74.0%
Conviction holders (share of 13F filers)
1.1%
Crowding (high-turnover and private-fund holders)
36.6%
Private-fund adviser ownership
32.5%
Active holders' share change QoQ
+3.5%
Holder tenure
10.5
Price vs estimated holder cost
-58.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.6%

Short interest

3 metrics
Short interest
4.9%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$46,587
Insider-sentiment score
31 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1484612 CUSIP 690145206 13F (30d) 37 filings 25 filers Visit website Investor relations